Search results
Results from the WOW.Com Content Network
NEW YORK (Reuters) -Martin Shkreli, known for once hiking the price of a life-saving drug more than 4,000%, cannot return to the pharmaceutical industry after a federal appeals court on Tuesday ...
Martin Shkreli (/ ˈ ʃ k r ɛ l i /; born March 17, 1983) is an American investor and businessman.Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
Shkreli was convicted of lying to investors and cheating them out of millions of dollars in two failed hedge funds he operated. Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015.
The justices turned away Shkreli's appeal of a lower court's decision upholding the penalty, equal to the profits he and one of his former companies made by raising the price of the drug Daraprim ...
Martin Shkreli must return $64.6 million in profits he and his former company reaped from jacking up the price and monopolizing the market for a lifesaving drug, a federal judge ruled Friday while ...
Martin Shkreli, the former pharmaceutical executive known for raising the price of a lifesaving drug more than 40-fold, has been released from prison, where he had been serving a seven-year term ...
The company was widely criticized for raising the price of daraprim by 5456% following its acquisition of rights to the drug in 2015. The company's stock price dropped around 10% after the price increase of the drug. [4] CEO Martin Shkreli faced immense criticism for his actions. [5]
The Turing Pharmaceuticals CEO promised to lower the drug price after hiking it up when his company acquired it. But it seems that isn't happening. Martin Shkreli won't cut individual Daraprim ...